moneyheap
APLS · Analysis updated Apr 1, 2026, 4:30 PM ET
Why is Apellis Pharmaceuticals, Inc. Common Stock (APLS) stock moving?
Apellis Pharmaceuticals (APLS) experienced a transformative event on March 31, 2026, when Biogen (BIIB) announced a definitive agreement to acquire the company for $41.00 per share in cash. This resulted in a massive price spike of approximately 135%, jumping from a previous close of $17.09 to over $40.00. The deal, valued at approximately $5.6 billion, includes a Contingent Value Right (CVR) that could provide up to an additional $4.00 per share based on sales milestones for Syfovre. Market data shows a massive volume spike (246,704 trades vs. a typical 25,000 range) accompanying this move. Following the news, major financial institutions including JP Morgan, Barclays, and Raymond James have downgraded the stock to Neutral or Market Perform, as the current price of $40.23 is now pinned near the $41.00 acquisition price. Investors are essentially treating APLS as a cash equivalent with minimal remaining upside until the deal's expected closure in Q2 2026.
News behind the analysis
- Biogen to Acquire Apellis Pharmaceuticals for $5.6 BillionBiogen (BIIB) has entered a definitive agreement to acquire Apellis for $41 per share in cash plus a contingent value right (CVR) worth up to $4.
- Apellis Stock Soars 140% on Takeover DealThe stock surged from a close of $16.97 on March 30 to over $40 following the announcement of the all-cash acquisition by Biogen.
- Barclays Raises Apellis Target to $41 Following AcquisitionBarclays adjusted its price target to match the $41 cash consideration, noting the deal represents a significant 140% premium.
- JP Morgan Downgrades APLS to Neutral, Raises Target to $41Analysts have moved to a Neutral/Hold rating as the stock price now aligns with the acquisition offer, limiting further upside.
- Raymond James Downgrades Apellis to Market PerformFollowing the merger news, Raymond James adjusted its rating to Market Perform, reflecting that the stock is now trading at its deal value.
- Biogen Lands Syfovre and Empaveli in Blockbuster DealThe deal adds two FDA-approved therapies to Biogen's portfolio, targeting geographic atrophy and rare kidney diseases.
- Apellis Announces FDA Acceptance for Empaveli sNDAPrior to the buyout news, the FDA granted Priority Review for Empaveli in C3G and primary IC-MPGN with a PDUFA date of July 28, 2025.
- Mikael Dolsten Joins Apellis Board of DirectorsFormer Pfizer R&D head Mikael Dolsten joined the board in March 2026, strengthening the company's strategic leadership.
- Apellis Reports Full Year 2025 Revenue of $689 MillionThe company reported strong commercial execution for Syfovre and Empaveli, setting the stage for the Biogen acquisition.
- Zacks: Apellis Stock Surges 135% on Merger NewsZacks confirms the stock's massive single-day gain was due to Biogen's $41 per share cash offer.
- apellis.comSource identified via Google Search grounding.
- stockstotrade.comSource identified via Google Search grounding.
- gurufocus.comSource identified via Google Search grounding.
- gurufocus.comSource identified via Google Search grounding.
- stocktitan.netSource identified via Google Search grounding.
- barchart.comSource identified via Google Search grounding.
- marketbeat.comSource identified via Google Search grounding.
- businessinsider.comSource identified via Google Search grounding.
- apellis.comSource identified via Google Search grounding.
- benzinga.comSource identified via Google Search grounding.
- apellis.comSource identified via Google Search grounding.
- public.comSource identified via Google Search grounding.
- investing.comSource identified via Google Search grounding.
- simplywall.stSource identified via Google Search grounding.
- pharmexec.comSource identified via Google Search grounding.